Sarcopenia remains largely undiagnosed and undertreated, because of the lack of a universally accepted definition, effective ways to measure it, and identification of the outcomes that should guide treatment efficacy. An ever growing number of clinicians and researchers along with funding and regulatory agencies have gradually recognized that sarcopenia is a human condition that requires both prevention and treatment. In this "Pharmacology in Perspective" article, we briefly reviewed sarcopenia; its common and less known pharmacological treatments, and attempted to define sarcopenia in its broader context, and presented some new ideas for potential future treatment for this devastating condition.
Introduction
To a large extent the term "sarcopenia", coined in 1988 by Dr. Irwin Rosenberg (Rosenberg, 1997) , has been very valuable in bringing needed attention to a pathological condition that has as devastating consequences as osteoporosis (Cooper et al., 2012; Malafarina et al., 2012; Verschueren et al., 2012) . Despite its importance and growing clinical recognition, sarcopenia remains largely undiagnosed and undertreated, because of the lack of a universally accepted definition, effective ways to measure it, and what outcomes should guide treatment efficacy (Fielding et al., 2011; Morley et al., 2011) .
Notwithstanding all these limitations, a larger number of clinicians and researchers along with funding and regulatory agencies have recognized that sarcopenia is a human condition that requires both prevention and treatment (Cruz-Jentoft et al., 2010; Chumlea et al., 2011; Morley et al., 2011; Biomarkers-Consortium-FNIH, 2012) . While many questions still remain unanswered, this should not limit us from moving this field of research and clinical practice forward by recognizing sarcopenia as a clinical entity for which treatments and interventions should be designed to limit its rather serious consequences (Chumlea et al., 2011; Morley et al., 2011) . Our "Pharmacology in Perspective" article does not claim to provide a comprehensive review of sarcopenia, rather we will focus on a brief working definition of this important condition and then highlight some of the most promising preventive measures and pharmacological interventions.
Sarcopenia: A working definition
A feasible, working definition of sarcopenia that we propose here, which literally means poverty of flesh, is "an aging-related condition that normally manifests during or after the 4 th decade of life where the overall quality of skeletal muscle decreases, ultimately leading to muscle weakness". It is fascinating to note that in rodents, primates, and humans muscle strength/power decrease significantly more than muscle mass itself, suggesting that it is the overall quality of the muscle that is affected and not necessarily the size or quantity of muscle (Rosenberg, 1997; Visser and Schaap, 2011) . For the individual, his family, and the clinician, perhaps the most important fact is that the sarcopenic individual is becoming weaker. In fact, grip strength, one of the best functional indicators of muscle weakness, strongly correlates with disability, morbidity, and mortality in the elderly (Ling et al., 2010; Taekema et al., 2010; Chen et al., 2012) .
Why prevent and treat sarcopenia?
Skeletal muscles are the largest organ system in the body, second to only water itself (Lukaski, 1997; Close et al., 2005; Gissel, 2005) . Skeletal muscles are also endocrine organs, and secrete myokines and other factors that influence distant organs and general health (Febbraio and Pedersen, 2005; Pedersen and Febbraio, 2008; Pedersen, 2011; Pedersen and Febbraio, 2012) . Fat and overall body metabolism are dependent on the quality of skeletal muscle and the load that skeletal muscles exert on bones along with the biochemical signaling from muscle to bone cells and vice-versa. Weaker individuals translate into weaker societies that are predisposed to a myriad of secondary diseases or at least at a higher risk of developing these diseases. In addition, muscle weakness leads or predisposes to mobility disability reenforcing the loss of muscle function. Significantly less mobile individuals, particularly when basic activities of daily living (ADL) are affected, become less independent and depressed.
Since it seems that we have evolved to only focus on problems that have a monetary consequence, the direct cost of sarcopenia was estimated to be in the 18-30 billion dollars range in 2004. In the turn of the 20 th century life expectancy in the US was ~49 years and in 2003 ~78 years. It is not an exaggeration to suggest that the real cost of sarcopenia in the US is in the hundreds of billions of dollars when accounting for both direct and indirect costs (Janssen et al., 2004 ).
In Fig. 1 a model is proposed where the main influences on the development of sarcopenia during aging are highlighted and the potential outcomes on its progression when this disease is and was able to demonstrate a 113% increase in muscle strength and 11.8% increase in gait velocity in the exercise groups (Fiatarone et al., 1994) . One cannot avoid commenting on the astronomical disconnect between muscle area and strength gains in these studies, which is what we call the corollary of all muscle aging studies in rodents and humans; the loss in strength/power is always significantly more than the loss of muscle mass in sedentary subjects, while the increase in strength/power is also more than the gain in muscle size when subjects are exercising, strongly suggesting that the key to muscle function is its quality and not necessarily its size. In fact, the myostatin knockout mouse model was a great disappointment (Gissel, 2005) , since the extremely larger muscles in those animals were not stronger as muscle physiologists had hoped for, certainly teaching us a lesson that more subtle, intrinsic mechanisms within muscles themselves, such as calcium homeostasis disruption, might be the culprit of these potent adaptations during aging (Gissel, 2005; Weisleder et al., 2006; Zhao et al., 2008; Romero-Suarez et al., 2010; Brotto, 2011; Thornton et al., 2011) .
Malafarina (Malafarina et al., 2012) has recently reviewed resistance exercise as an intervention and confirmed earlier studies through his extensive review of the literature that resistance exercise does improve muscle mass and strength, but alerts for three very important limitations: a) resistance exercise cannot be discontinued, otherwise the benefits are quickly lost; b) there are some intrinsic difficulties in exercising regularly, particularly for older individuals, and in special for those that lack social support; c) resistance exercise might not be sufficient to all subjects to reverse loss of muscle function, particularly in the elderly frail individuals (Liu and Latham, 2009) . Therefore, it is critical to develop pharmacological interventions that can be more effective than exercise, while being safer and broader in its spectrum of utilization. The next section reviews some of the most current interventions used for the treatment of sarcopenia.
How is sarcopenia being treated pharmacologically?
Active research on the use of pharmacological interventions against sarcopenia has grown significantly in the last decade, leading so far to more questions than answers with some controversial results. The most studied drugs have been: a) Testosterone: Testosterone (figure 2A) has proven effects to increase muscle mass and muscle function, but along with these beneficial effects there are also problematic side effects.
Reported side effects for testosterone are very diverse, some are quite mild: acne; bitter or strange taste in mouth; change in sex drive; fatigue; gum or mouth irritation; gum pain; gum tenderness or swelling; hair loss; headache. However, severe side effects can occur such as:
severe allergic reactions; change in the size or shape of the testicles; dark urine or light-colored bowel movements; depression or mood changes; dizziness; gingivitis; sleep apnea; loss of appetite; nausea; painful or prolonged erection; stomach pain; swelling of the ankles or legs; urination problems; and weight gain.
b) Growth hormone (GH):
Growth hormone is obviously highly effective in promoting bone and muscle growth and it has been approved by the FDA for a number of applications, which in practical terms means that the drug has acceptable safety in light of its benefits when used in the approved way. A common application of GH replacement therapy in adults is GH deficiency of either childhood-onset or adult-onset (usually as a result of an acquired pituitary tumor). GH can also be used to treat conditions that produce short stature but are not related to deficiencies in GH. Interestingly, outcomes are not as dramatic when compared to short stature that is exclusively attributable to deficiency of GH. It is as well very interesting that the FDA has approved the use of GH for muscle wasting associated with chronic HIV infection (Gilden, 1995) . Perhaps this application for a specific type of muscle wasting could be seen as a strong sign that GH could be useful in frail elderly subjects, but likely the major limitation of GH in clinical practice for the treatment of sarcopenia is the fact that the efficacy and safety of this use
for GH has not been tested in a double-blind clinical trial. Obviously a complex hormone that acts in the entire body in a myriad of systems will have important side effects (e.g., injection-site reaction joint swelling, joint pain, carpal tunnel syndrome, increased risk of diabetes (Liu et al., 2007) . While rare, patients can sometimes produce an immune response against GH, and GH may also be a risk factor for Hodgkin's lymphoma) (Freedman et al., 2005) . Certainly the complex biology of GH, the lack of clinical trials, and its side effects have limited its utilization for the treatment of sarcopenia.
c) Dehydroepiandrosterone (DHEA): Supplementation with DHEA ( figure 2B ) was reviewed in details by Malafarina and colleagues (Malafarina et al., 2012) . DHEA is an essential in the biosynthesis of androgen and estrogen sex steroids by functioning as a metabolic intermediate in pathway for the generation of these hormones, but more recent evidence also suggests that DHEA has its own biological activities independent of its functions related to sexual hormones Are these animals naturally more inactive due to their higher body weights? Researchers from the University of Missouri have published tantalizing data demonstrating that positive effects of myostatin KO might be dose dependent, since they found that the heterozygous mice (i.e., one gene was still active), had improved muscle performance (Gentry et al., 2011) . In humans thus far, myostatin has shown only therapeutic potential, but as the cell biology of myostatin effects are better understood this scenario could easily change.
f) Ursolic acid:
A very interesting acid present in apples, bilberries, cranberries, prunes, and also in several medicinal plants such as peppermint, rosemary, lavender, oregano, and thyme. It is very interesting that this acid has very potent anti-tumorigenic effects and is found in very large amounts in the apple peels (Shishodia et al., 2003; Pathak et al., 2007) . Ursolic acid ( figure 2D ) has also been found to be effective in treating mice with atrophy (Kunkel et al., 2011) . In this report, Kunkel and colleagues used a very clever combination of mice and human models of muscle research to show the beneficial effects of ursolic acid not only in muscle mass maintenance, but also on fat metabolism. In addition, there have been suggestions that humans that ingest animal protein sources along with apples may get additional benefits for muscle growth (Kunkel et al., 2011) . Since apple consumption has also been found to extend life span by 10% in drosophila, the old saying that "an apple a day may keep the doctor away" seems to have very deep scientific roots (Peng et al., 2011) .
g) Omega-3 acids:
The three main forms of omega-3 acids are: alpha-linolenic acid (ALA, figure 2G ), docosahexaenoic acid (DHA, figure 2H ), and eicosapentaenoic acid (EPA, figure 2I ).
While EPA and DHA are considered long-chain forms of omega-3 found in fish, some types of algae extracts, and fish oil supplements, ALA, the short-chain form, is found in plant sources like flax seed, walnuts, canola, and soybean oil. Omega-3 acids are generally recognized as antiinflammatory agents (Calder, 2003) , having been shown to prevent the damaging effects of TNF-α on muscle differentiation in vitro (Magee et al., 2008) Thus, it is possible to postulate that these acids could have unspecific beneficial effects linked to reduction of inflammation states that might characterize at least part of the aging process and the aging muscle. Yet another possibility is that these agents prevent the overall imbalance towards catabolism that develops during aging.
h) Angiotensin-converting enzyme (ACE) inhibitors:
A beneficial role in skeletal muscles (Onder et al., 2002; Onder et al., 2006) , including the prevention of sarcopenia (Sumukadas et al., 2006; Carter and Groban, 2008) has been suggested. It is interesting to note that benefits are more related to increased ability to exercise (Onder et al., 2006) . Are such effects related to improvement of cardiac function, or do ACE inhibitors (e.g., enalapril, figure 2E ) have direct effects on skeletal muscles? Here, it will be very interesting to consider the important work of Andrew Marks and colleagues. They have demonstrated that cardiac diseases lead to calcium leak mechanisms in skeletal muscles, suggesting important biochemical crosstalk between heart and skeletal muscle (Andersson and Marks, 2010) . Our groups have also recently found potential crosstalk mechanisms between heart and skeletal muscle as well as bone-muscle, muscle-bone, tendon-muscle. As we better understand the biological meaning of tissue crosstalk, new therapies for a host of diseases might be developed.
i) Proteasome inhibitors:
Bortezomib a common proteasome inhibitor has been found to upregulate MyoD and Myf-5. Interestingly, the effects on muscle degeneration are dependent on muscle-fiber type (Beehler et al., 2006) . In this report, the authors stated that "strangely, there is no rodent study examining the effect of these proteasome inhibitors to prevent muscle atrophy with aging", but the final conclusion is that proteasome inhibitors may not attenuate sarcopenia 
New Perspectives and a good "dose" of postulation:
The last 10 years have witnessed significant progress in antisense therapy for Duchenne muscular dystrophy (For a Review see (Nelson et al., 2009) ). Early studies demonstrated the feasibility of antisense oligonucleotides (AO) to remove a targeted dystrophin exon in mouse and human cells (Cole-Strauss et al., 1996; Cole-Strauss et al., 1997; Cole-Strauss et al., 1999; Albuquerque-Silva et al., 2001; Kren et al., 2002; Hu and Gatti, 2008; Nelson et al., 2009 ). Ongoing clinical trials for Duchenne muscular dystrophy are currently testing antisense-mediated exon skipping and forced read-through of premature stop codons (www.clinicaltrials.gov).
Interestingly, these approaches target the gene product rather than the gene itself. Thus, chimeric RNA/DNA oligonucleotides (chimeraplasts) may provide an alternative approach to treat muscle diseases caused by specific mutations, and this knowledge could be useful for the treatment of sarcopenia. Furthermore, in large screening studies it has been recently suggested that potential therapeutic approaches to target missense mutations are the use of tunicamycin, catanospermine, glycosylation inhibitors, or glycosidases (Hu and Gatti, 2008) . With these advances in different diseases and the sophistication of very large scale small compounds screening, there is significant hope that one or more of these agents will be effective to at least partially treat sarcopenia.
Equally promising will be the utilization of muscle stem cells to enhance the regenerative capacity of "old muscle". The new emerging field of bone-muscle crosstalk also promises to shed light into the twin diseases of aging, osteoporosis and sarcopenia. This new concept that bone and muscle cells can communicate biochemically and not only through physical forces is certainly paradigm shifting and as bone and muscle factors continue to be identified, one would expect that new therapeutical agents will be developed for sarcopenia (Brotto et al., 2010; Lang, 2011; Jähn et al., In Press) . Our labs have been experimenting with both heat shock therapy and a new device we developed to generate both electrical stimulation and pulsedelectromagnetic stimulation (PEMS). In vitro studies in our labs are very intriguing with these treatments being able to enhance myogenic differentiation and to produce larger muscle cells.
In conclusion, advances in our understanding of muscle biology (over the past decade) have led to potential new therapeutic approaches. When possible, these treatments should be combined with exercise and dietary supplements. Supplementation studies in rodents are urgently needed, and careful studies designed to understand the disconnect between muscle mass and muscle strength might hold the ultimate key for us to fully understand the biology, how to treat, and hopefully one day how to prevent sarcopenia, so that we might age graciously and strong, free from the devastating effects of muscle weakness. At last we will be able to say: and in-development agents could favor the balance towards anabolism and hypertrophy. It is important to observed that mechanisms that are not currently addressed by any of the compounds but seem to be affected by resistance exercise training are those that enhance muscle strength without necessarily increasing muscle mass.
